Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors

Novel Oncolytic Virotherapies will be developed by Transgene, based on its next generation Invir.IOTM Platform and expressing Randox’ Single-domain Antibodies (SdAb)   Strasbourg (France) and Belfast (Northern Ireland), October 2, 2017, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, and Randox, a global leader in in vitro … Continued

Read More